GURUFOCUS.COM » STOCK LIST » Financial Services » Capital Markets » Moelis & Co (NYSE:MC) » Definitions » Sloan Ratio %
中文

Moelis (Moelis) Sloan Ratio %

: -19.64% (As of Dec. 2023)
View and export this data going back to 2014. Start your Free Trial

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Moelis's Sloan Ratio for the quarter that ended in Dec. 2023 was -19.64%.

As of Dec. 2023, Moelis has a Sloan Ratio of -19.64%, indicating there is a warning stage of accrual build up.


Moelis Sloan Ratio % Historical Data

The historical data trend for Moelis's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moelis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sloan Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.88 -17.59 -35.66 10.56 -19.64

Moelis Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.56 -19.89 -22.63 -20.45 -19.64

Competitive Comparison

For the Capital Markets subindustry, Moelis's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Moelis Sloan Ratio % Distribution

For the Capital Markets industry and Financial Services sector, Moelis's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Moelis's Sloan Ratio % falls into.



Moelis Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Moelis's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2023 )-Cash Flow from Operations (A: Dec. 2023 )
-Cash Flow from Investing (A: Dec. 2023 ))/Total Assets (A: Dec. 2023 )
=(-24.7-158.472
-48.574)/1179.759
=-19.64%

Moelis's Sloan Ratio for the quarter that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Dec. 2023 )
=(-24.7-158.472
-48.574)/1179.759
=-19.64%

Moelis's Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was 3.666 (Mar. 2023 ) + -11.974 (Jun. 2023 ) + -10.732 (Sep. 2023 ) + -5.66 (Dec. 2023 ) = $-24.7 Mil.
Moelis's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 was -152.143 (Mar. 2023 ) + 71.155 (Jun. 2023 ) + 140.123 (Sep. 2023 ) + 99.337 (Dec. 2023 ) = $158.5 Mil.
Moelis's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 was 170.217 (Mar. 2023 ) + 1.815 (Jun. 2023 ) + -108.028 (Sep. 2023 ) + -15.43 (Dec. 2023 ) = $48.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Moelis  (NYSE:MC) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Dec. 2023, Moelis has a Sloan Ratio of -19.64%, indicating there is a warning stage of accrual build up.


Moelis Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Moelis's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Moelis (Moelis) Business Description

Traded in Other Exchanges
Address
399 Park Avenue, 4th Floor, New York, NY, USA, 10022
Moelis & Co is an independent investment bank that provides strategic and financial advice to a diverse client base, including corporations, financial sponsors, governments, and sovereign wealth funds. The company assists its clients in achieving their strategic goals by offering comprehensive, globally integrated financial advisory services across all industry sectors. It also advises clients on their critical decisions, including mergers and acquisitions, recapitalizations and restructurings, capital markets transactions, and other corporate finance matters. it generates revenue from advisory transactions. The firm derives a majority of its revenue from the United States followed by Europe and the rest of the World.
Executives
Kenneth Moelis director, 10 percent owner, officer: Chairman and CEO C/O MOELIS & COMPANY, 399 PARK AVENUE, 5TH FLOOR, NEW YORK NY 10022
Ciafone Katherine Pilcher officer: Chief Operating Officer 399 PARK AVE, NEW YORK NY 10022
Kenneth Shropshire director C/O MOELIS & COMPANY, 399 PARK AVENUE, 5TH FLOOR, NEW YORK NY 10011
Elizabeth Crain officer: Chief Operating Officer C/O MOELIS & COMPANY, 399 PARK AVENUE, 5TH FLOOR, NEW YORK NY 10022
Navid Mahmoodzadegan director, officer: Managing Director C/O MOELIS & COMPANY, 399 PARK AVENUE, 5TH FLOOR, NEW YORK NY 10022
Osamu R. Watanabe officer: General Counsel and Secretary C/O MOELIS & COMPANY, 399 PARK AVENUE, 5TH FLOOR, NEW YORK NY 10022
Jeffrey Raich director, officer: Managing Director C/O MOELIS & COMPANY, 399 PARK AVENUE, 5TH FLOOR, NEW YORK NY 10022
Christopher Callesano officer: SVP & Principal Acct Officer C/O MOELIS & COMPANY, 399 PARK AVENUE, 5TH FLOOR, NEW YORK NY 10022
Laila Worrell director 399 PARK AVENUE, NEW YORK NY 10022
Joseph Simon officer: Chief Financial Officer C/O MOELIS & COMPANY, 399 PARK AVENUE, 5TH FLOOR, NEW YORK NY 10022
Yolonda C Richardson director 399 PARK AVENUE, NEW YORK NY 10022
Leaman J Richard Iii director, officer: Managing Partner C/O MOELIS & COMPANY, 399 PARK AVENUE, 5TH FLOOR, NEW YORK NY 10022
John A Allison director PO BOX 1250, WINSTON SALEM NC 27102-1250
Yvonne Greenstreet director PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, PARSIPPANY NJ 07054
Eric Cantor director C/O MOELIS & COMPANY, 399 PARK AVENUE, 5TH FLOOR, NEW YORK NY 10022